WebORG STUDY ID : CTONG1702 NCT ID : NCT03574402 Conditions Carcinoma, Non-Small-Cell Lung Interventions Purpose This phase II, umbrella trial study directed by next generation sequencing (NGS) works in Chinese patients with advanced stage NSCLC who never received any anti-tumor treatment. WebMethods:Weinitiatedanumbrellatrial(CTONG1702),inthe8th armto access the efficacy and safety of AZD3759, an EGFR-TKI with high capability to penetrate the blood-brain barrier, in untreated EGFR-mutant NSCLC with brain or leptomeningeal metastases. Patients received AZD3759 200 mg or 300 mg BID. The primary objective was objective response rate ...
CTONG1901 took the lead in releasing the comparison results of …
WebJun 7, 2024 · Learn about the efficacy of several biomarker-driven agents, including tyrosine kinase inhibitors, in non-small-cell lung cancer patients. WebJun 20, 2024 · Full Title of Study: “An Open-label, Multi-center, Phase II Umbrella Study to Assess Efficacy of Targeted Therapy or Immunotherapy Directed by Next Generation Sequencing (NGS) in Chinese Patients With Advanced NSCLC (TRUMP)” Study Type Study Type: Interventional Study Design Allocation: Non-Randomized Intervention Model: … port washington wis weather
ELCC 2024: Efficacy and safety of AZD3759 in previously untreated …
WebMethods:Weinitiatedanumbrellatrial(CTONG1702),inthe8th armto access the efficacy and safety of AZD3759, an EGFR-TKI with high capability to penetrate the blood-brain barrier, in untreated EGFR-mutant NSCLC with brain or leptomeningeal metastases. Patients received AZD3759 200 mg or 300 mg BID. The primary objective was objective response rate ... WebAlpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases (PRNewswire) - "Alpha Biopharma...announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for … WebMethods. We initiated an umbrella trial (CTONG1702), in the 8 th arm to access the efficacy and safety of AZD3759, an EGFR-TKI with high capability to penetrate the blood-brain barrier, in untreated EGFR-mutant NSCLC with brain or leptomeningeal metastases. Patients received AZD3759 200 mg or 300 mg BID. The primary objective was objective … ironmongers trust